

OREGON CANCER INSTITUTE

Hematology-Oncology
3181 SW Sam Jackson Park Road, Portland OR 97239
Phone: 503-555-0400 | Fax: 503-555-0401
NPI: 1987654321

February 01, 2026

Blue Cross Blue Shield
Federal Employee Program
Prior Authorization Department
Medical Review Unit

RE: Letter of Medical Necessity

Patient Name:	Sarah Mitchell
Date of Birth:	1973-08-14
Member ID:	FEP334829176
Group Number:	FEP-STANDARD-2024
Medication Requested:	Lisocabtagene maraleucel (Breyanzi)
Diagnosis:	Diffuse large B-cell lymphoma, unspecified site (C83.30)

To Whom It May Concern:

I am writing on behalf of my patient, Sarah Mitchell, to document the medical necessity of Lisocabtagene maraleucel (Breyanzi) for the treatment of Diffuse large B-cell lymphoma, unspecified site. This letter provides clinical documentation supporting the need for this medication and demonstrates that my patient meets the coverage criteria for this therapy.

CLINICAL HISTORY AND DIAGNOSIS

52-year-old female with relapsed/refractory DLBCL. Originally diagnosed March 2024 with Stage IIIB disease. Received first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) x6 cycles with initial complete response. Relapsed at 8 months. Received second-line R-ICE (rituximab, ifosfamide, carboplatin, etoposide) x3 cycles — partial response but not eligible for autologous stem cell transplant due to insufficient stem cell mobilization. Third-line gemcitabine/oxaliplatin/rituximab x4 cycles with progressive disease on restaging PET/CT. Now referred for CAR-T cell therapy.

CURRENT DISEASE ACTIVITY

Most recent assessment (2026-01-10):

- Ann Arbor Stage: IIIB
- Ecog Performance Status: 1
- Ecog Interpretation: Restricted in physically strenuous activity but ambulatory
- Ipi Score: 3
- Ipi Risk Category: High-intermediate
- Disease Status: relapsed_refractory
- Lines Of Therapy Completed: 3

PRIOR TREATMENT HISTORY

The patient has tried and/or completed the following therapies:

- **R-CHOP** (2024-03-15 to 2024-08-20)

Outcome: Achieved complete metabolic response on end-of-treatment PET/CT (Deauville 2). Relapsed at 8 months with new cervical and retroperitoneal lymphadenopathy.

- **R-ICE** (2025-05-01 to 2025-07-15)

Outcome: Partial metabolic response (Deauville 4). Stem cell mobilization attempted but failed — insufficient CD34+ yield. Not eligible for autologous transplant.

- **GemOx-R** (2025-09-01 to 2025-12-15)

Outcome: Progressive disease on restaging PET/CT with new hepatic lesions. Biopsy-confirmed persistent DLBCL.

MEDICAL NECESSITY SUMMARY

Based on the clinical evidence presented, Lisocabtagene maraleucel (Breyanzi) is medically necessary for Sarah Mitchell. The patient has a confirmed diagnosis of Diffuse large B-cell lymphoma, unspecified site (ICD-10: C83.30). Key criteria met: Biopsy-confirmed DLBCL (ICD-10 C83.30). CD19-positive on immunohistochemistry.; Patient is 52 years old (≥ 18); Rituximab included in all 3 prior lines (R-CHOP, R-ICE, GemOx-R); Doxorubicin (anthracycline) included in first-line R-CHOP. I respectfully request approval of this prior authorization.

Please contact my office if you require any additional clinical information.

Sincerely,

Dr. Rachel Nguyen, MD, FACP

Hematology-Oncology

NPI: 1987654321

Date: 02/01/2026